Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis

REFERENCES

1. 1.↵
   1. Brandt J,
   2. Khariouzov A,
   3. Listing J,
   4. et al

   . Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Davis JC, Jr,
   2. van der Heijde D,
   3. Braun J,
   4. et al

   . Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230–6.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Calin A,
   2. Dijkmans BA,
   3. Emery P,
   4. et al

   . Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594–600.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Gorman JD,
   2. Sack KE,
   3. Davis JC, Jr

   . Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349–56.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Davis JC,
   2. van der Heijde D,
   3. Dougados M,
   4. Woolley JM

   . Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494–501.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Braun J,
   2. McHugh N,
   3. Singh A,
   4. Wajdula JS,
   5. Sato R

   . Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 2007;46:999–1004.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Davis JC, Jr,
   2. van der Heijde DM,
   3. Braun J,
   4. et al

   . Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346–52.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. van der Linden S,
   2. Valkenburg HA,
   3. Cats A

   . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.

   OpenUrlPubMed
9. 9.↵
   1. Anderson JJ,
   2. Baron G,
   3. van der Heijde D,
   4. Felson DT,
   5. Dougados M

   . Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. van der Heijde D

    . ASsessment in ankylosing spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386–94.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Wanders AJ,
    2. Landewe RB,
    3. Spoorenberg A,
    4. et al

    . What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622–32.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Creemers MC,
    2. Franssen MJ,
    3. van ‘t Hof MA,
    4. Gribnau FW,
    5. van de Putte LB,
    6. van Riel PL

    . Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    Surveillance, Epidemiology, and End Results (SEER) program public-use data (1973–1999) [11 registries, 1992–1999)], National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission. Internet. Available at: http:www.seer.cancer.gov [Accessed April 13, 2009].
14. 14.↵
    1. Davis JC,
    2. van der Heijde DM,
    3. Braun J,
    4. et al

    . Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557–62.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Klareskog L,
    2. Gaubitz M,
    3. Rodriguez-Valverde V,
    4. Malaise M,
    5. Dougados M,
    6. Wajdula J

    . A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other DMARDs (3-year interim report). Ann Rheum Dis 2006;65:1578–84.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Davis JC,
    2. van der Heijde D,
    3. Braun J,
    4. et al

    . Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003;48:3230–6.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Feltelius N,
    2. Ekbom A,
    3. Blomqvist P

    . Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–95: a population based cohort study. Ann Rheum Dis 2003;62:1185–8.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Askling J,
    2. Klareskog L,
    3. Blomqvist P,
    4. Fored M,
    5. Feltelius N

    . Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006;65:1184–7.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Brophy S,
    2. Pavy S,
    3. Lewis P,
    4. et al

    . Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001;28:2667–73.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Sandborn WJ,
    2. Hanauer SB,
    3. Katz S,
    4. et al

    . Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–94.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Marzo-Ortega H,
    2. McGonagle D,
    3. O’Connor P,
    4. Emery P

    . Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74–6.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. et al

    . Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639–47.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Wajdula J,
    2. Sridharan S,
    3. Fletcher T,
    4. MacPeek D,
    5. Meier E

    . Rates of IBD in patients receiving etanercept and placebo in AS. Arthritis Rheum 2007;56:S256–7.

    OpenUrl
24. 24.↵
    1. Gran JT,
    2. Skomsvoll JF

    . The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766–71.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Sieper J

    . Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447–51.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Guignard S,
    2. Gossec L,
    3. Salliot C,
    4. et al

    . Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631–4.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Lim LL,
    2. Fraunfelder FW,
    3. Rosenbaum JT

    . Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–52.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Baraliakos X,
    2. Listing J,
    3. Rudwaleit M,
    4. Brandt J,
    5. Sieper J,
    6. Braun J

    . Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462–6.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. van der Heijde D,
    2. Landewe R,
    3. Einstein S,
    4. et al

    . Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324–31.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. van der Heijde D,
    2. Landewé R,
    3. Baraliakos X,
    4. et al

    . Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063–70.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Schett G,
    2. Landewe R,
    3. van der Heijde D

    . Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007;66:709–11.

    OpenUrlFREE Full Text
32. 32.↵
    1. Diarra D,
    2. Stolina M,
    3. Polzer K,
    4. et al

    . Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156–63.

    OpenUrlCrossRefPubMed